Non-invasively extendable megaprosthesis
Non-invasively extendable megaprosthesis
批准号:
10818977
负责人:
Jeffrey David Gordon
金额:
$93.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-25 至 2025-07-31
关键词:
AdolescentBone neoplasmsCadaverChildClinicalComplexComplicationContralateralDevelopmentDevice or Instrument DevelopmentDevicesDiagnosisDistalElectromagneticsElectronicsEngineeringExcisionFDA approvedFailureFatigueFemurFractureFundingGrowthHomeImplantInfectionJointsKneeLateralLeadLegLengthLimb SalvageLimb structureMagnetic Resonance ImagingMalignant Bone NeoplasmManualsMechanicsMedialMotorOncologyOperative Surgical ProceduresOrthopedicsPatientsPhasePopulationPreparationPriceProsthesisReportingResectedSideSkinSurgeonSurgical InstrumentsSystemTestingTrainingUnited StatesValidationbonechemotherapycommercializationdesigndesign and constructiondesign,build,testimplant designimplantationindustry partnerinfection rateinstrumentmanufacturabilitymanufacturenovelprototypesealsimulationtreatment choicetumortumor diagnosis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
This project is the development of a non-invasively extending distal femur replacement
(DFR) for children and adolescents subsequent to bone tumor resection. Each year in
the US there are 200-250 malignant bone tumor diagnoses in the distal femurs of
patients 15 years and younger. With advances in chemotherapy, limb salvage surgery
utilizing a megaprosthesis has increasingly become the treatment of choice. For
growing patients these megaprostheses are required to extend so they can “grow” as
the contralateral limb grows. Only one non-invasively lengthened DFR is FDA approved
to treat these patients. The implant is actuated with a large electromagnetic appliance in
a clinical setting. It is exceedingly complex and the average revision rate has been
reported at 48%, including revisions for: insufficient lengthening capacity, lengthening
mechanism failure, implant fracture, aseptic loosening and infection. MRI is
contraindicated and the implant is extremely expensive. Our device is non-invasively,
manually extended by pressing on the patient's skin. It's designed for a significantly
reduced complication rate, the mechanism is simple and robust, it's MRI compatible and
can be lengthened at home for a more gradual growth and constant leg length equality.
It is capable of up to 240% of the extension that its sole US competitor offers and is
easier and less expensive to manufacture so it can be offered at a reduced price to a
greater population. The specific aims of the project are to (1) complete the implant
design, (2) design specialized surgical instruments for implantation and (3) conduct non-
clinical bench testing in preparation for FDA submission.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金